- Home
- HAFN vs SYRE Comparison
HAFN vs SYRE Comparison
Compare HAFN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | SYRE |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HAFN | SYRE |
|---|---|---|
| Price | $6.10 | $32.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $56.50 |
| AVG Volume (30 Days) | ★ 1.3M | 616.6K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $2,221,808,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.30 | N/A |
| P/E Ratio | $10.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.61 | $10.91 |
| 52 Week High | $6.64 | $35.31 |
Technical Indicators
Market Signals| Indicator | HAFN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 53.08 |
| Support Level | $5.63 | $31.52 |
| Resistance Level | $6.25 | $34.03 |
| Average True Range (ATR) | 0.13 | 1.85 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 76.42 | 48.71 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.